Tempus (TEM) Price-to-Projected Revenue Ratio

Symbol and logo of brand Tempus (TEM)

The forward P/S valuation history of Tempus AI, Inc (TEM) demonstrates the impact of its clinical data library, which is monetized through contracts with pharmaceutical behemoths, with the current level sitting around 8.90. Growth is driven by the creation of the Tempus One AI ecosystem, which is becoming the standard for oncologists. The platform's digital scalability enables the instantaneous analysis of millions of records, providing physicians with paid insights without additional physical costs.

Tempus AI, Inc. - TEM Forward Price-to-Revenue Multiple (period 12/31/2024 - 11/13/2026)

TEM (Tempus Labs): analytical breakdowns and indicator data

- current price and projected stock value:
- market capitalization details:
Analysis of all company metrics:Tempus TEM
Product sample of Tempus AI, Inc

Assessing the financial stability of Tempus AI, Inc (TEM) requires an analysis of the ratio between market capitalization and expected revenue. This indicator measures the premium the market is willing to pay for future sales growth, separating the long-term trend from market noise. By analyzing the forward P/S ratio, an investor can determine whether the costs of aggressively recruiting expensive AI specialists through stock options are justified relative to the pace of business scaling.

Competitor analysis for Tempus AI, Inc

Forward P/S Multiple QGEN (Qiagen)|Market Cap to Expected Sales Ratio Ionis Pharmaceuticals, Inc. (IONS)|RGEN - Price-to-Projected Revenue Ratio|RNA (Avidity Corp) - Market Cap to Projected Revenue|CRSP: Forward P/S Multiple|Forward Price-to-Revenue Multiple genedx.com|Forward Price-to-Revenue Multiple RARE|BEAM (Beam Therapeutics Inc) - Price to Expected Revenue Ratio|Forward P/S Multiple SRPT|TWST - Market Cap to Future Revenue Ratio|Price-to-Projected Revenue Ratio 10x Genomics, Inc. TXG|NTLA - Forward Price-to-Revenue Multiple|Stoke Therapeutics, Inc. - Forward P/S Multiple|BLFS (BioLife Solutions Inc) - Market Cap to Projected Revenue|Wave Life Sciences Corp (WVE) - Price-to-Projected Revenue Ratio|Market Cap to Projected Revenue MAZE|SION (Sionna Therapeutics Inc) - Forward P/S Multiple|Forward P/S Multiple primemedicine.com|Forward Price-to-Revenue Multiple TSHA (Taysha Gene Therapies, Inc.)|Price to Expected Revenue Ratio QURE|Forward P/S Multiple MGTX (MeiraGTx PLC)|REGENXBIO Corp (RGNX) - Market Cap to Future Revenue Ratio|SLDB - Price-to-Projected Revenue Ratio|ocugen.com (OCGN) - Forward Price-to-Revenue Multiple|PacBio (PACB) - Price-to-Projected Revenue Ratio|Future Price to Revenue BNTC (Benitec Biopharma Inc)|Forward Price-to-Revenue Multiple DSGN|Forward P/S Multiple Rocket Corp|Price-to-Projected Revenue Ratio 4D Molecular Therapeutics (FDMT)|Market Cap to Expected Sales Ratio lexeotx.com|Korro Bio - Forward Price-to-Revenue Multiple|Forward Price to Sales EDIT|Silence Therapeutics Inc. - Forward P/S Multiple|PRQR - Forward P/S Multiple|CDXS: Forward P/S Multiple|SGMO - Market Cap to Expected Sales Ratio|Forward Price-to-Revenue Multiple NAUT|MGX: Forward Price to Sales|Forward P/S Multiple DTIL|Market Cap to Expected Sales Ratio generationbio.com|Price-to-Projected Revenue Ratio Boundless Bio, Inc. BOLD|XCUR: Market Cap to Projected Revenue|Celsion Corporation - Forward P/S Multiple|Phio Pharmaceuticals (PHIO) - Forward Price-to-Revenue Multiple|MBIO (mustangbio.com) - Forward Price-to-Revenue Multiple|RNAZ: Price to Expected Revenue Ratio|BNGO (Bionano Genomics Inc.) - Forward P/S Multiple|Market Cap to Future Revenue Ratio adnas.com APDN|Price-to-Projected Revenue Ratio bluebird bio (BLUE)|Forward Price-to-Revenue Multiple immunoprecise.com IPA|Forward P/S Multiple OMGA (Omega)|OMIC: Market Cap to Projected Revenue|RGLS - Price-to-Projected Revenue Ratio|SYRS (syros.com) - Market Cap to Projected Revenue|TBIO: Forward P/S Multiple|TRACON Pharmaceuticals Inc. (TCON) - Forward P/S Multiple|Forward Price-to-Revenue Multiple UBX